Overview

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

Status:
Terminated
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Galapagos NV